Merck to forge ahead with CETP-inhibiting cholesterol med

An independent data-monitoring panel recommended that Merck & Co. ($MRK) continue studying its cholesterol-fighting CETP inhibitor, anacetrapib. The drugmaker had added a futility analysis to the study, dubbed REVEAL, after rival drugmaker Eli Lilly & Co. ($LLY) canned development of its CETP drug evacetrapib. Pfizer ($PFE) and Roche ($RHHBY) had previously given up on their own CETP meds. Report

Suggested Articles

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.